Osteoporosis results in loss of bone mineral density and increased risk of fracture. Several clinical trials have indicated that romosozumab treatment is associated with increased bone mineral density (BMD). However, the efficacy and safety of this new drug are not well documented. Therefore in this meta-analyses, it was shown that 210 mg romosozumab treatment resulted in a significantly lower risk of fracture.

A systematic review and meta-analysis of randomised controlled trials was conducted to determine the efficiency and safety of Romosozumab in the management of postmenopausal osteoporosis.

The EMBASE, Web of Science, PubMed, and Cochrane Controlled Trials Registry were searched comprehensively to found RCTs. The incidence of fractures, changes in the lumbar spine, total hip and femoral neck bone mineral density (BMD), AND adverse events were considered as the study outcomes. Finally, a total of six trials were selected.  

A significantly lower risk of new vertebral, hip and non-vertebral fracture were noticed with Romosozumab than other therapies. The BMD was also remarkably enhanced at the femoral neck, lumbar spine, and total hip than the placebo. No change was seen in the incidence of adverse events among the patients with Romosozumab compared to other approaches.

The Romosozumab 210 mg monthly proven to be effective and well tolerated among the postmenopausal women with osteoporosis with high fracture risk.